Lincoln Pharmaceuticals Sees Marginal Profit Rise in Q4

Lincoln Pharmaceuticals reported a modest profit increase to Rs 11.63 crore for the fourth quarter ending March 2026, compared to Rs 11.57 crore a year earlier. Revenue grew by 13.5% to Rs 183.08 crore. The company aims for Rs 1,000 crore revenue within three years, focusing on new market expansion.

Lincoln Pharmaceuticals announced a slight increase in profit to Rs 11.63 crore for the fourth quarter ending in March 2026, a small uptick from the Rs 11.57 crore earned in the same period the previous year.

The company's revenue from operations significantly rose by 13.5%, reaching Rs 183.08 crore during the quarter, up from Rs 161.30 crore in the final quarter of FY25. For the entire fiscal year 2025-26, the company saw a consolidated net profit rise of over 6% to Rs 87.89 crore.

Annual revenues reached Rs 704.48 crore, reflecting a 9.10% increase from the previous year's Rs 645.71 crore. Lincoln Pharmaceuticals has also proposed an 18% dividend, equating to Rs 1.80 per share for the fiscal year 2025-26.

With aspirations to hit Rs 1,000 crore in revenue within three years, Lincoln Pharmaceuticals plans to expand its business into high-value product lines and tap into new markets.